References
- Korting H C, Kerscher M J, Schäfer-Korting M. Topical glucocorticoids with improved benefit/risk ratio: do they exist?. J Am Acad Dermatol 1992; 27: 87–92
- Ishihara M, Itoh M, Jinbo Y. Comparative study by the double-blind method of hydrocortisone 17-butyrate 21-propionate (HBP) external preparation. Nishi Nippon Hifu 1981; 23: 828–44
- HBP Study Group. Comparative clinical studies on the effect of 0.1% hydrocortisone 17-butyrate 21-propionate (Pandel ointment and cream) by the double-blind method. Nishinihon J Dermatol 1982; 44: 644–56
- Takeda K. Systemic effects of an external preparation, hydrocortisone 17-butyrate 21-propionate: comparison by double-blind test of betamethasone 17-valerate (0.12%) ointment and hydrocortisone 17-butyrate (0.1%) ointment. Jpn J Dermatol 1982; 92: 503–13
- Kitano Y. Hydrolysis of hydrocortisone 17-butyrate 21-propionate by cultured human keratinocytes. Acta Derm Venerea (Stockh) 1986; 66: 98–102
- Stoughton R B. Percutaneous absorption of drugs. Annu Rev Pharmacol Toxicol 1989; 29: 55–69
- Wendt B, Stähle H. Drug-Monitoring mit einem neuen Kortikosteroid-Ester. Der Dtsch Dermatol 1990; 38: 1472–8
- Hisa T, Katoh J, Yoshioka K, et al. Contact allergies to topical corticosteroids. Contact Dermatitis 1993; 28: 174–9